Application of the ATP-cell viability assay for assessment of biologic response modifiers in gynecologic cancer.
Angioli
R
R
University of Miami School of Medicine, Department of Obstetrics and Gynecology, Fla.
Sevin
B U
BU
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D000255:Adenosine Triphosphate; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002470:Cell Survival; D003131:Combined Modality Therapy; D004353:Drug Evaluation, Preclinical; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D011836:Radiation Tolerance; D011980:Receptors, Progesterone / Q000187:drug effects; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D007155:Immunologic Factors; D016898:Interferon-alpha; D011980:Receptors, Progesterone; D016899:Interferon-beta; D000255:Adenosine Triphosphate